- Last edited on September 28, 2021
Differences
This shows you the differences between two versions of the page.
cl:huntingtons-disease [on July 2, 2019] |
cl:huntingtons-disease [on July 2, 2019] |
||
---|---|---|---|
Line 27: | Line 27: | ||
</WRAP> | </WRAP> | ||
</WRAP> | </WRAP> | ||
+ | |||
+ | ===== Pathophysiology ===== | ||
+ | The pathophysiology and neurochemical bases of Huntington's are poorly understood. Dopamine and glutamate transmission is hypothesized to be affected, leading to striatal and cortical changes resulting in motor dysfunction such as chorea. | ||
===== Symptoms ===== | ===== Symptoms ===== | ||
Line 48: | Line 51: | ||
</WRAP> | </WRAP> | ||
+ | ===== Treatment ===== | ||
+ | ==== Motor ==== | ||
+ | Chorea is one of the core symptoms of Huntington's, and when there is significant motor dysfunction, this needs to be treated. Untreated chorea can worsen weight loss and increase falls risk. Tetrabenazine (up to 100 mg/day), amantadine (300–400 mg/day), or riluzole (200 mg/day) can be prescribed. Adverse effects such as depression, suicidality, parkinsonism (with tetrabenazine), and elevated liver enzymes (with riluzole) should be monitored for. | ||
+ | |||
+ | * [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677041/|Videnovic, A. (2013). Treatment of huntington disease. Current treatment options in neurology, 15(4), 424-438.]] | ||
+ | ==== Psychiatric ==== | ||